Atrial Flutter

• 

  Subject Areas on Research

  • "Typical" cavotricuspid isthmus-dependent atrial flutter without the cava. 
  • 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 
  • A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. 
  • ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration with the Heart Rhythm Society. 
  • ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. 
  • Acute and long-term efficacy and safety of catheter cryoablation of the cavotricuspid isthmus for treatment of type 1 atrial flutter. 
  • Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. 
  • Atrial arrhythmias during chronic follow-up of surgery for complex congenital heart disease. 
  • Atrial fibrillation after pulmonary transplant. 
  • Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. 
  • Atrial flutter, atrial fibrillation, and other primary atrial tachycardias. 
  • Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. 
  • Biatrial maze procedure versus pulmonary vein isolation for atrial fibrillation during mitral valve surgery: New analytical approaches and end points. 
  • COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. 
  • Conduction velocity in the tricuspid valve-inferior vena cava isthmus is slower in patients with type I atrial flutter compared to those without a history of atrial flutter. 
  • Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series. 
  • Dronedarone in high-risk permanent atrial fibrillation. 
  • Emergency ventricular pacing from the esophagus in infancy. 
  • In-hospital management of patients with atrial flutter. 
  • Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. 
  • Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. 
  • Maximum voltage-guided catheter ablation of typical atrial flutter: making a good procedure even better? 
  • Modification of the maze procedure for atrial flutter and atrial fibrillation. I. Rationale and surgical results. 
  • Modification of the maze procedure for atrial flutter and atrial fibrillation. II. Surgical technique of the maze III procedure. 
  • New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance. 
  • Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. 
  • Performance of a new cardiac cryoablation system in the treatment of cavotricuspid valve isthmus-dependent atrial flutter. 
  • Predicting atrial fibrillation and flutter using electronic health records. 
  • Radiofrequency catheter ablation for the treatment of human type 1 atrial flutter. Identification of a critical zone in the reentrant circuit by endocardial mapping techniques. 
  • Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. 
  • Reduction in Inappropriate ICD Therapy in MADIT-RIT Patients Without History of Atrial Tachyarrhythmia. 
  • Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT. 
  • Surgical treatment of supraventricular tachyarrhythmias. 
  • Surgical treatment of the Wolff-Parkinson-White syndrome and other supraventricular tachyarrhythmias. 
  • The relation of quinidine-induced elevation of serum digoxin concentration to the conversion of atrial fibrillation-flutter: a pilot study. 
  • The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. 
• 

  Keywords of People

  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology